Table 1.

Final study cohort

Characteristics:		Case subjects (n=128)	Control subjects (n=70)	Test statistic	p-value
Age	Mean[±SD]	49.0 [±15.9]	50.6 [±18.3]	t=0.63	0.532
Males	N (%)	59 (46%)	27 (39%)	X2=1.04	0.307
Females		69 (54%)	43 (61%)
White/Caucasian		110 (86%)	52 (74%)	X2=4.13	0.248
African American		16 (13%)	16 (23%)
Asian		1 (1%)	1 (1%)
Hispanic/Latino		7 (6%)	3 (4%)	X2=0.13	0.716
Allergic rhinitis / response		70 (55%)	18 (26%)	X2=15.39	<0.001
Asthma		57 (45%)	1 (1%)	X2=40.59	<0.001
Allergic fungal sinusitis		7 (6%)	0 (0%)	X2=3.97	0.046
AERD / ASA sensitivity		19 (15%)	0 (0%)	X2=11.49	0.001
Nasal polyposis		75 (59%)	0 (0%)	X2=66.03	<0.001
Current smoker		5 (4%)	4 (6%)	X2=0.34	0.559
Diabetes mellitus (Type I/II)		14 (11%)	5 (7%)	X2=0.75	0.386
GERD		35 (27%)	6 (9%)	X2=9.71	0.002
CRS metrics
LM CT total score	Mean[±SD]	13.6 [±5.6]	----	----	----
LK Endoscopy total score		7.1 [±3.5]	----	----	----
SNOT-22 total score		49.8 [±22.2]	----	----	----
Olfactory metrics
Sniffin’ Sticks total score		21.7 [±9.5]	30.4 [±5.8]	t=6.91	<0.001
Threshold (T) score		3.7 [±3.0]	6.7 [±2.5]	t=7.36	<0.001
Discrimination (D) score		9.1 [±3.5]	11.5 [±2.4]	t=5.22	<0.001
Identification (I) score		9.0 [±4.3]	12.1 [±2.3]	t=5.60	<0.001
QOD-NS total score		12.9 [±11.2]	4.3 [±5.8]	t= −5.97	<0.001
OCES		4.7 [±3.9]	0.6 [±1.0]	t= −8.19	<0.001
OC Anterior opacification (%)		57% [±32%]	----	----	----
OC Middle opacification (%)		63% [±29%]	----	----	----
OC Posterior opacification (%)		68% [±29%]	----	----	----

SD, standard deviation; AERD, aspirin exacerbated respiratory disease; ASA, acetylsalicyclic acid; GERD, gastroesophageal reflux disease; LM CT, Lund-Mackay computed tomography; LK, Lund-Kennedy; SNOT-22, 22-item SinoNasal Outcome Test; QOD-NS, Questionnaire of Olfactory Dysfunction-Negative Statements; OCES, olfactory cleft endoscopy score; OC, olfactory cleft.